دورية أكاديمية
Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Updated Systematic Review and Analysis of Treatment Strategies.
| العنوان: | Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Updated Systematic Review and Analysis of Treatment Strategies. |
|---|---|
| المؤلفون: | Naga HI; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Mellia JA; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Basta MN; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Morris MP; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Christopher AN; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Campbell FM; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Sommers K; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Levinson H; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Nelson JA; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Fischer JP; From the Division of Plastic Surgery, Duke University; Division of Plastic Surgery and Biomedical Library, Perelman School of Medicine, University of Pennsylvania; Plastic Surgery Foundation; and Plastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center. |
| المصدر: | Plastic and reconstructive surgery [Plast Reconstr Surg] 2022 Oct 01; Vol. 150 (4), pp. 762-769. Date of Electronic Publication: 2022 Jul 22. |
| نوع المنشور: | Journal Article; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 1306050 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-4242 (Electronic) Linking ISSN: 00321052 NLM ISO Abbreviation: Plast Reconstr Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: Baltimore : Williams & Wilkins, |
| مواضيع طبية MeSH: | Breast Implantation*/adverse effects , Breast Implants*/adverse effects , Breast Neoplasms*/etiology , Breast Neoplasms*/surgery , Lymphoma, Large-Cell, Anaplastic*/diagnosis , Lymphoma, Large-Cell, Anaplastic*/etiology , Lymphoma, Large-Cell, Anaplastic*/therapy, Female ; Humans ; Seroma/etiology |
| مستخلص: | Background: Although guidelines have been published on treatment of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL), there has been no comprehensive analysis of BIA-ALCL treatment variation based on the available literature. The authors sought to assess current treatment strategies of BIA-ALCL relative to current guidelines. Methods: Database searches were conducted in June of 2020. Included articles were case reports and case series with patient-level data. Collected variables included clinicopathologic features, implant characteristics, diagnostic tests, ALCL characteristics, treatment, and details of follow-up and outcome. Treatment data from before and after 2017 were compared with National Cancer Center Network guidelines. Results: A total of 89 publications were included and 178 cases of BIA-ALCL were identified. Most patients presented with seroma ( n = 114, 70.4 percent), followed by a mass ( n = 14, 8.6 percent), or both ( n = 23, 14.2 percent). Treatment included en bloc capsulectomy of the affected implant in 122 out of 126 cases with treatment details provided (96.8 percent). Radiation therapy was given in 38 cases (30.2 percent) and chemotherapy was given in 71 cases (56.3 percent). Practitioners used less chemotherapy for local disease after treatment guideline publication in 2017 ( p < 0.001), whereas treatment for advanced disease remained unchanged ( p = 0.3). There were 10 recurrences and eight fatalities attributable to BIA-ALCL, which were associated with advanced presentation (29 versus 2.1 percent; OR, 19.4; 95 percent CI, 3.9 to 96.3; p < 0.001). Conclusions: BIA-ALCL remains a morbid but treatable condition. Current guidelines focus treatment for local disease and reduce nonsurgical interventions with radiation or chemotherapy. Patients presenting with advanced BIA-ALCL experience higher rates of recurrence and mortality. (Copyright © 2022 by the American Society of Plastic Surgeons.) |
| References: | Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997;100:554–555. Kadin ME, Adams WP Jr, Inghirami G, Di Napoli A. Does breast implant-associated ALCL begin as a lymphoproliferative disorder? Plast Reconstr Surg. 2020;145:30e–38e. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: Long-term follow-up of 60 patients. J Clin Oncol. 2014;32:114–120. Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: A systematic review. JAMA Surg. 2017;152:1161–1168. Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants. Plast Reconstr Surg. 2019;143:30S–40S. Nelson JA, Dabic S, Mehrara BJ, et al. Breast implant-associated anaplastic large cell lymphoma incidence: Determining an accurate risk. Ann Surg. 2020;272:403–409. Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020;73:841–846. Gidengil CA, Predmore Z, Mattke S, van Busum K, Kim B. Breast implant-associated anaplastic large cell lymphoma: A systematic review. Plast Reconstr Surg. 2015;135:713–720. National Cancer Center Network. T-cell lymphoma guidelines. Available at: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf . Accessed January 20, 2021. McCarthy CM, Loyo-Berríos N, Qureshi AA, et al. Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial report of findings, 2012–2018. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):65S–73S. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2017;37:285–289. American Association of Plastic Surgeons. 2019 Plastic surgery statistics. Available at: https://www.plasticsurgery.org/news/plastic-surgery-statistics?sub=2019+Plastic+Surgery+Statistics . Accessed January 20, 2021. Coroneos CJ, Selber JC, Offodile AC 2nd, Butler CE, Clemens MW. US FDA breast implant postapproval studies: Long-term outcomes in 99,993 patients. Ann Surg. 2019;269:30–36. Doren EL, Miranda RN, Selber JC, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139:1042–1050. de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4:335–341. Magnusson M, Beath K, Cooter R, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. Plast Reconstr Surg. 2019;143:1285–1292. Tandon VJ, DeLong MR, Ballard TN, et al. Evolving trends in textured implant use for cosmetic augmentation in the United States. Plast Reconstr Surg. 2018;142:1456–1461. Swanson E. Plastic surgeons defend textured breast implants at 2019 U.S. Food and Drug Administration hearing: Why it is time to reconsider. Plast Reconstr Surg Glob Open 2019;7:e2410. Swanson E, Hall-Findlay E. Banning textured implants is a rational decision to eliminate the risk of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). Aesthet Surg J. 2020;40:NP474–NP477. U.S. Food and Drug Administration. Statement from FDA principal deputy commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on FDA’s new efforts to protect women’s health and help to ensure the safety of breast implants. Published March 24, 2020. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-principal-deputy-commissioner-amy-abernethy-md-phd-and-jeff-shuren-md-jd-director-fdas . Accessed January 24, 2021. Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2018;141:586e–599e. Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34:160–168. Campanale A, Spagnoli A, Lispi L, Boldrini R, Marletta M. The crucial role of surgical treatment in BIA-ALCL prognosis in early- and advanced-stage patients. Plast Reconstr Surg. 2020;146:530e–538e. Tevis SE, Hunt KK, Miranda RN, et al. Breast implant-associated anaplastic large cell lymphoma: A prospective series of 52 patients. Ann Surg. 2022;275:e245–e249. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology 2008;1:280–288. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3:209–225. Richardson K, Alrifai T, Grant-Szymanski K, et al. Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature. Mol Clin Oncol. 2017;6:539–542. Stack A, Levy I. Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma. Clin Case Rep. 2019;7:1003–1006. Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep. 2018;6:634–637. |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20220721 Date Completed: 20220930 Latest Revision: 20231002 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9551598 |
| DOI: | 10.1097/PRS.0000000000009538 |
| PMID: | 35862104 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1529-4242 |
|---|---|
| DOI: | 10.1097/PRS.0000000000009538 |